AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis

RegulatoryapprovedRINVOQPositive

AI Analysis

Summary

AbbVie announced European Commission approval of RINVOQ (upadacitinib) for treating active polyarticular juvenile idiopathic arthritis in children aged 2 years and older who are inadequate responders or intolerant to DMARDs. The approval was based on Phase 1 data.

Clinical Trial Data

Phase

Phase 1

Outcome Details

European Commission approval for treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years and older who have responded inadequately to or are intolerant to one or more DMARDs

Importance:7/10

Sentiment:

0.85

regulatory approvalEuropean Commissionpediatric indicationrheumatologyRINVOQJAK inhibitor

Related Companies

$ABBV

Read the original article

Published by PR Newswire Biotech on September 22, 2026 6:00 AM

Read Original